Vimian, a veterinary company, has been downgraded to a "sell" recommendation by UBS due to its current share price being considered perfect. The target price of SEK 35 remains unchanged.

UBS's analysis reveals that Vimian's shares are trading at a premium of approximately 70 percent compared to the sector, which is higher than the average premium for medium-sized European medical technology firms with sales growth between 7 to 13 percent CAGR. UBS expresses concerns about Vimian's market valuation, suggesting that it reflects expectations of flawless execution, leaving no room for error. The bank also highlights potential risks to Vimian's growth momentum, noting that while the company has achieved double-digit organic growth in five of the last eight quarters, the combination of high valuation and these risks justifies the downgrade.